Table 1 Clinical and demographic Characteristics.

From: Development and validation of a prognostic model for nasal cavity squamous cell carcinoma based on the SEER database

Variables

Total

Training

Validation

P

(n = 580)

(n = 406)

(n = 174)

Age, n (%)

   

0.623

< 60years

207 (36)

148 (36)

59 (34)

 

≥ 60years

373 (64)

258 (64)

115 (66)

 

Sex, n (%)

   

0.829

Female

178 (31)

123 (30)

55 (32)

 

Male

402 (69)

283 (70)

119 (68)

 

Race, n (%)

   

0.516

White

515 (89)

364 (90)

151 (87)

 

Black

31 (5)

19 (5)

12 (7)

 

Other

34 (6)

23 (6)

11 (6)

 

Marital status, n (%)

   

0.29

Single

120 (21)

86 (21)

34 (20)

 

Married

337 (58)

241 (59)

96 (55)

 

Other

123 (21)

79 (19)

44 (25)

 

Tumor size, n (%)

   

0.312

< 2 cm

221 (38)

154 (38)

67 (39)

 

< 4, ≥2

213 (37)

156 (38)

57 (33)

 

≥ 4 cm

146 (25)

96 (24)

50 (29)

 

Grade, n (%)

   

0.209

I

113 (19)

83 (20)

30 (17)

 

II

266 (46)

183 (45)

83 (48)

 

III

195 (34)

138 (34)

57 (33)

 

IV

6 (1)

2 (0)

4 (2)

 

SCS, n (%)

   

0.16

Localized

282 (49)

201 (50)

81 (47)

 

Regional

151 (26)

111 (27)

40 (23)

 

Distant

147 (25)

94 (23)

53 (30)

 

AJCC Stage, n (%)

   

0.5

I

257 (44)

183 (45)

74 (43)

 

II

106 (18)

78 (19)

28 (16)

 

III

57 (10)

36 (9)

21 (12)

 

IV

160 (28)

109 (27)

51 (29)

 

T Stage, n (%)

   

0.204

T1-T2

387 (67)

278 (68)

109 (63)

 

T3-T4

193 (33)

128 (32)

65 (37)

 

N Stage, n (%)

   

0.592

N0-N1

540 (93)

376 (93)

164 (94)

 

N2-N3

40 (7)

30 (7)

10 (6)

 

M Stage, n (%)

   

0.136

M0

571 (98)

402 (99)

169 (97)

 

M1

9 (2)

4 (1)

5 (3)

 

Surgery, n (%)

   

0.79

No

98 (17)

67 (17)

31 (18)

 

Yes

482 (83)

339 (83)

143 (82)

 

lymphadenectomy, n (%)

   

0.956

No

509 (88)

357 (88)

152 (87)

 

Yes

71 (12)

49 (12)

22 (13)

 

Radiation, n (%)

   

0.196

No

345 (59)

234 (58)

111 (64)

 

Yes

235 (41)

172 (42)

63 (36)

 

Chemotherapy, n (%)

   

0.346

No

461 (79)

318 (78)

143 (82)

 

Yes

119 (21)

88 (22)

31 (18)

 

Systemic therapy, n (%)

   

0.775

No

498 (86)

347 (85)

151 (87)

 

Yes

82 (14)

59 (15)

23 (13)

 
  1. SCS, SEER combined stage; AJCC, American Joint Committee on Cancer.